帕尼培南/倍他米隆与美罗培南在治疗急性白血病并发感染中的临床研究

目的评价帕尼培南和美罗培南治疗急性白血病并发感染时的临床疗效及安全性。方法急性白血病并发感染患者80例,随机分成两组,帕尼培南/倍他米隆组和美罗培南组,观察两组的临床疗效和不良反应。结果帕尼培南/倍他米隆组40例,有效率80%,细菌清除率80.9%,美罗培南组40例,有效率82.5%,细菌清除率82.6%。两组比较差异无统计学意义（P〉0.05）。结论应用帕尼培南和美罗培南治疗急性白血病并发感染的患者疗效可靠、安全性好。

A clinlcal study of panipenem/betamipron and meropenem in patients with acute leukemia and complicated infections

Objective To evaluate the clinical efficacy and safety of panipenem/betamipron and meropenem in the treatment of patients with acute leukemia and infections.Methods A randomized study was conducted in 80 patients with acute leukemia and bacterial infections.They were divided to panipenem/betamipron group and meropenem group,the clinical efficacy and side-effect were observed between two groups.Results The effective rate and bacterial clearance rate in panipenen/betamipron group were 80% and 80.9% respectively,while 82.5% and 82.6% respectively in meropenem group.There was no significant difference between two groups.Conclusion Panipenen/betamipron has characteristics to treat patients suffered from acute leukemia combined with infection rapidly and obviously.Panipenen/betamipron is significantly effect and safe in the treatment of acute leukemia with infections.Its efficacy and adverse reaction are similar to that of meropenem.